1-1-1991

Pursuing Product Modifications and New Products: The Role of Organizational Control Mechanisms in Implementing Innovation Strategies in the Pharmaceutical Industry

Laura B. Cardinal
Southern Methodist University

Follow this and additional works at: https://scholar.smu.edu/business_workingpapers

Part of the Business Commons

This document is brought to you for free and open access by the Cox School of Business at SMU Scholar. It has been accepted for inclusion in Historical Working Papers by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu.
PURSUING PRODUCT MODIFICATIONS AND NEW PRODUCTS: 
THE ROLE OF ORGANIZATIONAL CONTROL MECHANISMS IN 
IMPLEMENTING INNOVATION STRATEGIES IN THE 
PHARMACEUTICAL INDUSTRY 

Working Paper 91-121* 

by 

Laura B. Cardinal 

Laura B. Cardinal 
Edwin L. Cox School of Business 
Southern Methodist University 
Dallas, Texas 75275 
(214) 692-4103 

* This paper represents a draft of work in progress by the 
author and is being sent to you for information and review. 
Responsibility for the contents rests solely with the author 
and may not be reproduced or distributed without her written 
consent. Comments are encouraged. Please address all cor­ 
respondence to Laura B. Cardinal.
Table of Contents

I. Executive Summary
II. Purpose of the Study
III. Definitions
   • Strategic Intent Variables
   • Control Mechanism Variables
   • Innovation Variables
IV. Research Method
   • Sample and Sample Selection
   • Data and Measures
   • Sample Characteristics
V. Primary Findings
   • Influence of Strategic Intent on the Number of Product Modifications and New Products
   • Influence of Input Control Mechanisms on the Number of Product Modifications and New Products
   • Influence of Process Control Mechanisms on the Number of Product Modifications and New Products
   • Influence of Output Control Mechanisms on the Number of Product Modifications and New Products

Laura B. Cardinal is a faculty member in strategic management at the Edwin L. Cox School of Business at Southern Methodist University. She earned her Ph.D. at The University of Texas at Austin. Prof. Cardinal is an active speaker and researcher. She is active in several professional organizations including The Academy of Management, Strategic Management Society, and The Institute of Management Sciences.

This research was supported in part by the National Science Foundation, The University of Texas Research Institute, and the Bonham Research Fund of The University of Texas. The author would like to thank Richard A. Levy, National Pharmaceutical Council; Kenneth W. Kirk, College of Pharmacy, The University of Texas; Andreas M. Pleil, Pharmaco, Inc.; Thomas G. Gerding, Drug Dynamics Institute, The University of Texas; and Harold Bober, Paul de Haen for their contributions to this research. The author is also indebted to the 101 senior level managers who provided detailed information about their firms. The study would not have been possible without their help and time.
Executive Summary

It is widely believed that firms pursuing product modification strategies require one set of control mechanisms and that firms pursuing new product strategies require a different set of control mechanisms (Dewar & Dutton, 1986; Ettlie, Bridges, & O'Keefe, 1984; Kaluzny, Veney, & Gentry, 1984). However, few studies have examined the role of innovation strategies and control mechanisms in the innovation creation process. Using data from 45 pharmaceutical firms I investigated the effects of innovation strategies and formal control mechanisms on innovation outcomes. The findings suggest the following:

- First, strategic intent does not have a direct effect on innovation outcomes as hypothesized. Theories that focus on intended strategies did not receive support in this study. These results are consistent with the recent anecdotal evidence in business publications that suggest that the desire to be innovative and the commitment of innovation-targeted resources does not help organizations realize innovation outcomes (O'Reilly, 1991; Vanston, 1988).

- Second, it appears that control plays a more critical role than expected in the innovation creation process. Control mechanism effects were clear and systematic, although, not always supporting the hypotheses based on the literature. The results suggest that the innovation process is not stochastic and that managers can use formal control mechanisms to proactively guide the process.

- Third, the determinants of product modifications and new products do not appear to be different. All three types of control mechanisms, input, process, and output, were found to be positively related to both the number of product modifications and new products.

- Fourth, although strategic intent did not have a direct effect on innovation outcomes, it does have an indirect effect on innovation outcomes through control mechanisms. Although not explicitly tested in this research, strategic intent had a direct effect on control mechanisms, which in turn affected innovation outcomes. The results clearly suggest that managers must choose control mechanisms that support innovation strategies.

Purpose of the Study

Although innovation strategies (strategic goals) and realized innovation outcomes (product modifications and new products) represent different endpoints of the innovation process, little empirical work exists that has attempted to link innovation strategies and innovation outcomes. The overall purpose of this research was to study formal mechanisms that managers can use to influence the innovation process in their R&D laboratories to successfully realize innovation goals. More specific subgoals are listed as follows:

- First, this project examines the determinants of the innovation creation process in R&D laboratories. Prior research examining the determinants of innovation has focused on innovation adoption (e.g., once the NOW checking account was created at one bank, NOW accounts were adopted by the rest of the banking industry), but not innovation creation. Researchers examining innovation creation have described innovations across a product's life cycle (e.g., automobiles, starting with the Ford Model T), but not the determinants of the technical innovations themselves (Abernathy & Clark, 1988; Tushman & Anderson, 1986).

- Second, the project examines the match between innovation strategies and control mechanisms and their corresponding affects in achieving product modifications versus new products. It was hypothesized that different innovation strategies (the strategic intent to pursue product modifications versus the strategic intent to pursue new products) require differential control mechanisms. Specifically, it was expected one set of control mechanisms would enhance the pursuit of product modifications, and that the same set of control mechanisms would hamper the pursuit of new products.

- Third, the project examines a more encompassing set of control mechanisms than previously studied. Although process control mechanisms (targeting behaviors and activities) have been the most studied type of control, they also have been the least recommended form of control when the transformation process is uncertain; for example in the research and development process. Therefore this project also looked at input controls (specialist diversity, specialist depth, and professionalization) and output controls (goal specificity, emphasis on outcomes in evaluation, and rewards and bonuses linked to results), in addition to process controls (centralization, documentation, formalization, frequency of performance appraisals).

Definitions

Strategic Intent Variables

- **Strategic Intent to Pursue New Products/Drugs** - The extent to which top management emphasizes new product development as a vital element of its strategy and as a means to compete.

- **Strategic Intent to Pursue Product Modifications** - The extent to which top management emphasizes improvements to existing products as a vital element of its strategy and as a means to compete.

- **R&D Spending/Sales** - average R&D spending as a percentage of sales for 1979-83.

- **Targeted Percent of Sales from New Products** - Targeted percentage of sales from new products for 1979-83.

Organizational Control Variables

- **Use of Input Control Mechanisms** - The extent to which control mechanisms control for the degree and variety of core knowledge, skills, experiences, and attitudes displayed on the job for R&D professionals.
  
  - **Specialist Diversity** - the number of different scientific specialties
  
  - **Special Depth** - the degree to which personnel are concentrated in a few core specialities.
  
  - **Professionalization** - the number of years of specialized schooling and the propensity to seek contact with professional colleagues outside the immediate work setting.

- **Use of Process Control Mechanisms** - The extent to which control mechanisms are used to regulate and monitor activities and behaviors displayed by R&D professionals.
  
  - **Centralization** - the degree of decision-making authority at lower levels of the organization hierarchy.
  
  - **Documentation** - the amount of record-keeping of work behaviors required by R&D professionals.
  
  - **Formalization** - the extent that rules governing behavior are precisely and explicitly formulated.
  
  - **Frequency of Performance Appraisals** - the number of times behavior is measured and evaluated.

- **Use of Output Control Mechanisms** - The extent to which control mechanisms are used to control results and outcomes produced by R&D professionals.
  
  - **Goal Specificity** - the extent to which goals are explicitly, clearly defined, and provide unambiguous criteria for selecting among alternative outcomes.
  
  - **Rewards and Bonuses Linked to Results** - the degree of public recognition R&D professionals receive for outstanding achievements.
  
  - **Emphasis on Outcomes** - the degree to which the quantity of outcomes is emphasized in performance appraisals and rewards.

Innovation Variables

- **New Products** - were drugs approved by the FDA representing chemical structures never previously available in the U.S. to treat a particular disease (New Chemical Entities).

- **Product Modifications** - were drugs involving new dosage forms, new indications, formula changes, name changes, and status changes.
Research Method

Sample and Sample Selection

A comprehensive list of U.S. pharmaceutical firms was developed using multiple sources: the National Pharmaceutical Council's membership list, the Pharmaceutical Manufacturers Association's membership list, the Generic Association's membership list, Medical Advertising News (Top 50 Pharmaceutical Firms Special Issue), Paul de Haen's New Product Survey and New Product Index, Pharmaceutical Manufacturers of the United States, R&D Laboratories in the U.S., Physician's Desk Reference, and Approved Drug Products with Therapeutic Equivalence Evaluations. After excluding firms that no longer existed, were duplicate listings, or had no in-house R&D, a final sample population of 154 firms remained. Fifty-five agreed to participate and provided full or partial data, constituting a response rate of 35.71%. Forty-five complete sets of questionnaires were completed by both the CEO (or a Senior Level Manager) and R&D Director and used for this study. Fourteen of the firms in the sample were members of the National Pharmaceutical Council.

Data Collection

Two primary types of data collection methods were used for this study: archival data collection and questionnaire data collection methods. An archival data methodology was used to collect data for innovation outcomes. A questionnaire methodology was used to collect data for strategic intent and control mechanisms.

Innovation data was collected from archival sources from 1984-1988. CEOs were asked retrospective questions concerning strategic intent to innovate during 1979-1983. R&D Directors were asked retrospective questions concerning control mechanisms in their firms' R&D laboratories during 1979-1983.
### Sample Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Average</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Senior Level Manager</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years in Current Position</td>
<td>7.24</td>
<td>1.00 to 31.00</td>
</tr>
<tr>
<td>Years in Firm</td>
<td>14.18</td>
<td>2.00 to 31.00</td>
</tr>
<tr>
<td>Years in Industry</td>
<td>17.70</td>
<td>2.00 to 36.00</td>
</tr>
<tr>
<td><strong>R&amp;D Director</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years in Current Position</td>
<td>6.47</td>
<td>1.00 to 36.00</td>
</tr>
<tr>
<td>Years in Firm</td>
<td>13.58</td>
<td>1.00 to 37.00</td>
</tr>
<tr>
<td>Years in Industry</td>
<td>18.29</td>
<td>1.00 to 37.00</td>
</tr>
<tr>
<td><strong>Business Unit</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of Employees</td>
<td>2722.68</td>
<td>11.00 to 31,500</td>
</tr>
<tr>
<td>ROI</td>
<td>14.90</td>
<td>-2.50 to 42.45</td>
</tr>
<tr>
<td>ROA</td>
<td>9.90</td>
<td>-2.50 to 42.45</td>
</tr>
<tr>
<td>Number of New Products (NCEs)</td>
<td>.87</td>
<td>0.00 to 11.00</td>
</tr>
<tr>
<td>Number of Product Modifications</td>
<td>3.56</td>
<td>0.00 to 14.00</td>
</tr>
<tr>
<td><strong>R&amp;D Laboratory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of Employees in R&amp;D Laboratory(ies)</td>
<td>370.87</td>
<td>1.00 to 3356.00</td>
</tr>
<tr>
<td>R&amp;D Spending/Sales</td>
<td>12.45</td>
<td>2.45 to 32.45</td>
</tr>
<tr>
<td>Targeted Percent of Sales from New Products</td>
<td>22.45</td>
<td>2.45 to 52.45</td>
</tr>
</tbody>
</table>
Primary Findings
Influence of Strategic Intent on the Number of Product Modifications and New Products

Do pharmaceutical firms with a higher level of commitment to product modifications exhibit a greater number of product modifications and new products?

Average Level of Strategic Intent to Pursue Product Modifications

Do pharmaceutical firms with a higher level of commitment to new products exhibit a greater number of product modifications and new products?

Average Level of Strategic Intent to Pursue New Products
Influence of Strategic Intent on the Number of Product Modifications and New Products

(continued)

Do pharmaceutical firms that spend a higher level of R&D spending as a percentage of sales exhibit a greater number of product modifications and new products?

**Average Level of R&D Spending as a Percentage of Sales**

- Product Modifications
- New Products

Do pharmaceutical firms that target a higher percentage of sales to be generated from new products exhibit a greater number of product modifications and new products?

**Average Percentage of Sales to Be Generated from New Products**

- Product Modifications
- New Products
Comments:

In general, there were few differences between pharmaceutical firms with respect to achieving higher level of product modifications and new products for the strategic intent variables. The only exception was that firms that exhibited higher levels of commitment to new products exhibited a higher level of product modifications (note that this was the only statistically significant finding for the strategic intent variables).
Influence of Input Control Mechanisms on the Number of Product Modifications and New Products

Do pharmaceutical firms with higher levels of specialist diversity in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Specialist Diversity

<table>
<thead>
<tr>
<th></th>
<th>Product Modifications</th>
<th>New Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIGH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Do pharmaceutical firms with higher levels of specialist depth in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Specialist Depth

<table>
<thead>
<tr>
<th></th>
<th>Product Modifications</th>
<th>New Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIGH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Influence of Input Control Mechanisms on the Number of Product Modifications and New Products

(continued)

Do pharmaceutical firms with higher levels of professionalization in their R&D laboratories exhibit a greater number of product modifications and new products?

<table>
<thead>
<tr>
<th>Average Level of Professionalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Modifications</td>
</tr>
<tr>
<td>New Products</td>
</tr>
</tbody>
</table>

Comments:

Pharmaceutical firms with higher levels of specialist diversity and professionalization and lower levels of specialist depth exhibited higher levels of product modifications and new products (note that effects of specialist diversity, specialist depth, and professionalization on product modifications and new products were statistically significant).
Influence of Process Control Mechanisms on the Number of Product Modifications and New Products

Do pharmaceutical firms with higher levels of centralization in their R&D laboratories exhibit a greater number of product modifications and new products?

![Bar chart showing the relationship between average level of centralization and product modifications/new products.](chart_1)

Do pharmaceutical firms with higher levels of documentation in their R&D laboratories exhibit a greater number of product modifications and new products?

![Bar chart showing the relationship between average level of documentation and product modifications/new products.](chart_2)
Influence of Process Control Mechanisms on the Number of Product Modifications and New Products

(continued)

Do pharmaceutical firms with higher levels of formalization in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Formalization

[Diagram showing the relationship between average level of formalization and product modifications/new products with data points marked as LOW and HIGH]

Do pharmaceutical firms with higher levels of frequency of performance appraisals in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Frequency of Performance Appraisals

[Diagram showing the relationship between average level of frequency of performance appraisals and product modifications/new products with data points marked as LOW and HIGH]
Influence of Process Control Mechanisms on the Number of Product Modifications and New Products

(continued)

Comments:

Pharmaceutical firms with higher levels of centralization, documentation, formalization, and frequency of performance appraisals exhibited higher levels of product modifications and new products (note that effects of documentation and frequency of performance appraisals on product modifications and new products were statistically significant, while centralization and formalization were not).
Influence of Output Control Mechanisms on the Number of Product Modifications and New Products

Do pharmaceutical firms with higher levels of goal specificity in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Goal Specificity

- Product Modifications
- New Products

Do pharmaceutical firms with a greater emphasis on outcomes in their R&D laboratories exhibit a greater number of product modifications and new products?

Average Level of Emphasis on Outcomes

- Product Modifications
- New Products
Influence of Output Control Mechanisms on the Number of Product Modifications and New Products

(continued)

Do pharmaceutical firms with higher levels of rewards and bonuses linked to results in their R&D laboratories exhibit a greater number of product modifications and new products?

<table>
<thead>
<tr>
<th>Average Level of Rewards and Bonuses Linked to Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Modifications</td>
</tr>
<tr>
<td>LOW</td>
</tr>
</tbody>
</table>

0.00 20.00 40.00 60.00

Comments:

Pharmaceutical firms with higher levels of goal specificity, emphasis on outcomes, and rewards and bonuses linked to results exhibited higher levels of product modifications and new products (note that effects of emphasis on outcomes and rewards and bonuses linked to results on product modifications and new products were statistically significant, while goal specificity was not).
Note: The following is a partial list of papers that are currently available in the Edwin L. Cox School of Business Working Paper Series. When requesting a paper, please include the Working Paper number as well as the title and author(s), and enclose payment of $2.50 per copy made payable to SMU. A complete list is available upon request from:

Business Information Center
Edwin L. Cox School of Business
Southern Methodist University
Dallas, Texas 75275
"Organizational Subcultures in a Soft Bureaucracy: Resistance Behind the Myth and Facade of an Official Culture," by John M. Jermier, John W. Slocum, Jr., Louis W. Fry, and Jeannie Gaines

"Global Strategy and Reward Systems: The Key Roles of Management Development and Corporate Culture," by David Lei, John W. Slocum, Jr., and Robert W. Slater

"Multiple Niche Competition - The Strategic Use of CIM Technology," by David Lei and Joel D. Goldhar

"Global Strategic Alliances," by David Lei and John W. Slocum, Jr.

"A Theoretical Model of Household Coupon Usage Behavior And Empirical Test," by Ambuj Jain and Arun K. Jain

"Household's Coupon Usage Behavior: Influence of In-Store Search," by Arun K. Jain and Ambuj Jain

"Organization Designs for Global Strategic Alliances," by John W. Slocum, Jr. and David Lei

"Option-like Properties of Organizational Claims: Tracing the Process of Multinational Exploration," by Dileep Hurry

"A Review of the Use and Effects of Comparative Advertising," by Thomas E. Barry


"Designing Global Strategic Alliances: Integration of Cultural and Economic Factors," by John W. Slocum, Jr. and David Lei

"The Components of the Change in Reserve Value: New Evidence on SFAS No. 69," by Mimi L. Alciatore

"Asset Returns, Volatility and the Output Side," by G. Sharathchandra